As a gain-of-function mutation, novel inhibitors targeting KRAS G12C have recently been developed and have entered clinical trials, the most impactful being AMG510 (Sotorasib) and MRTX849 (Adagrasib), which have received accelerated approval from the US Food and Drug Administration (FDA) for the treatment of non-small cell lung cancer (NSCLC) with the KRAS-G12C mutation [15,16,17]. Here, KRAS is linked to non-small cell lung carcinoma.